At PTAB, Mylan Blasts AstraZeneca Over $3.5B Diabetes Meds
Mylan Pharmaceuticals Inc. waged an assault Wednesday on the patent behind AstraZeneca AB's $3.5 billion diabetes drugs Onglyza and Kombiglyze, arguing in front of a Patent Trial and Appeals Board panel...To view the full article, register now.
Already a subscriber? Click here to view full article